<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106040</url>
  </required_header>
  <id_info>
    <org_study_id>NEO3-09</org_study_id>
    <nct_id>NCT01106040</nct_id>
  </id_info>
  <brief_title>Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes</brief_title>
  <official_title>A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navidea Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navidea Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data from this pivotal clinical trial will be used to support a marketing application (i.e.,&#xD;
      NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in&#xD;
      the lymphatic pathway draining the primary site of a tumor.&#xD;
&#xD;
      Multicenter, open-label, within-patient comparative study of Lymphoseek and vital blue dye in&#xD;
      the detection of excised lymph nodes in patients with known melanoma and breast cancer. All&#xD;
      patients will receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc&#xD;
      99m and vital blue dye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with primary melanoma and breast cancer, lymph node status is often a strong&#xD;
      predictor of outcome and influences the course of treatment a patient may follow after&#xD;
      surgery. In an effort to reduce the morbidity and costs of detection of lymph node&#xD;
      metastases, surgical oncologists have developed a method by which the sentinel lymph node&#xD;
      (SLN; the first node in a draining basin) is identified intraoperatively and removed. This&#xD;
      technique, called sentinel node biopsy, has extremely high negative predictive values for&#xD;
      melanoma metastases and breast cancer metastases. The two largest trials for melanoma,&#xD;
      Morton, et al (2005) and Rossi, et al (2006), reported false negative rates of 6.3% and&#xD;
      14.7%, respectively. Morton, et al (2006), in perhaps the most mature trial reported to date,&#xD;
      showed a false negative rate of 3.4%. There is growing evidence that sentinel node biopsy&#xD;
      will have a significant impact on the management of melanoma. Sentinel node biopsy also has&#xD;
      extremely high negative predictive values for breast cancer metastases; the false-negative&#xD;
      rates range from 0% to 9%. There is growing evidence that sentinel node biopsy will have a&#xD;
      significant impact on the management of breast cancer. Although the survival and local&#xD;
      recurrence studies have yet to be completed, the technique has emerged into common practice.&#xD;
&#xD;
      Intraoperative lymphatic mapping (ILM) with a radiopharmaceutical is a nuclear medicine&#xD;
      examination which identifies for the surgeon the first lymph node to receive lymphatic flow&#xD;
      from the primary tumor site. This node is removed and analyzed for the presence of malignant&#xD;
      cells. By locating the lymph node prior to surgery, a small incision can be used to remove&#xD;
      the node and a smaller dissection can be employed. The high negative predictive value of the&#xD;
      technique seems to provide an accurate staging procedure and may spare patients who are lymph&#xD;
      node negative the morbidity of a complete lymph node dissection. Consequently, staging of&#xD;
      melanoma by lymph node mapping and biopsy may be equivalent to regional node dissection&#xD;
      without the attendant post surgical morbidity.&#xD;
&#xD;
      An ideal lymph node imaging agent would exhibit rapid clearance from the injection site,&#xD;
      rapid uptake and high retention within the first draining lymph node, and low uptake by the&#xD;
      remaining lymph nodes. The ideal agent would also have low radiation absorption; high&#xD;
      biological safety; convenient, rapid, and stable technetium-99m labeling; and biochemical&#xD;
      purity.&#xD;
&#xD;
      Lymphoseek (Technetium Tc 99m diethylenetriaminepentaacetic acid mannosyl dextran, [Tc 99m]&#xD;
      DTPA Mannosyl Dextran) is a radiotracer that accumulates in lymphatic tissue by binding to a&#xD;
      mannose binding protein that resides on the surface of dendritic cells and macrophages.&#xD;
      Lymphoseek is a macromolecule consisting of multiple units of DTPA and mannose, each&#xD;
      synthetically attached to a 10 kilodalton dextran backbone. The mannose acts as a substrate&#xD;
      for the receptor, and the DTPA serves as a chelating agent for labeling with Tc 99m.&#xD;
&#xD;
      Lymphoseek has a diameter of about 5 nm, which is substantially smaller than current agents&#xD;
      used for targeting lymphoid tissue. Lymphoseek's small diameter permits enhanced diffusion&#xD;
      into lymph nodes and blood capillaries, resulting in a rapid injection site clearance. Upon&#xD;
      entry into the blood, the agent binds to receptors in the liver or is filtered by the kidney&#xD;
      and accumulates in the urinary bladder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance of Blue Dye and Lymphoseek</measure>
    <time_frame>Surgery after injections of Lymphoseek and blue dye</time_frame>
    <description>The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reverse Concordance of Blue Dye and Lymphoseek</measure>
    <time_frame>Surgery after injections of Lymphoseek and blue dye</time_frame>
    <description>The proportion of lymph nodes detected intraoperatively by Lymphoseek that were also detected by blue dye.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Lymphoseek, Lymphatic mapping, Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lymphoseek</intervention_name>
    <description>The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.</description>
    <arm_group_label>Lymphoseek, Lymphatic mapping, Injection</arm_group_label>
    <other_name>technetium Tc 99m tilmanocept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient has provided written informed consent with HIPAA authorization.&#xD;
&#xD;
          2. The patient is a candidate for surgical intervention, with lymph node mapping being a&#xD;
             part of the surgical plan.&#xD;
&#xD;
          3. The patient is at least 18 years of age at the time of consent.&#xD;
&#xD;
          4. The patient has an ECOG performance status of Grade 0 - 2 (see Appendix A).&#xD;
&#xD;
          5. The patient has a clinical negative node status at the time of study entry (i.e. T0-4,&#xD;
             N0, M0, see Appendix D and E).&#xD;
&#xD;
          6. If of childbearing potential, the patient has a negative pregnancy test within 72&#xD;
             hours prior to administration of Lymphoseek, has been surgically sterilized, or has&#xD;
             been postmenopausal for at least 1 year.&#xD;
&#xD;
             Melanoma Patients&#xD;
&#xD;
          7. The patient has a diagnosis of primary melanoma. Breast Cancer Patients&#xD;
&#xD;
          8. The patient has a diagnosis of primary breast cancer.&#xD;
&#xD;
          9. Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph&#xD;
             node biopsy is part of the surgical plan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient is pregnant or lactating.&#xD;
&#xD;
          2. The patient has clinical or radiological evidence of metastatic cancer including&#xD;
             palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0,&#xD;
             see Appendix D and E).&#xD;
&#xD;
          3. The patient has a known hypersensitivity to Lymphazurin.&#xD;
&#xD;
          4. The patient has participated in another investigational drug study within 30 days of&#xD;
             scheduled surgery.&#xD;
&#xD;
             Melanoma Patients&#xD;
&#xD;
          5. The patient has a tumor with a Breslow depth less than 0.75mm.&#xD;
&#xD;
          6. Patient has had preoperative chemotherapy, immunotherapy, or radiation therapy.&#xD;
&#xD;
          7. Patient has been diagnosed with a prior invasive melanoma that would occur on the same&#xD;
             body region or potentially draining to the same nodal basin or patients with truncal&#xD;
             or extremity primary melanoma who has had a prior breast cancer potentially draining&#xD;
             to the same axillary nodal basin.&#xD;
&#xD;
          8. Patient has undergone node basin surgery of any type or radiation to the nodal&#xD;
             basin(s) potentially draining the primary melanoma.&#xD;
&#xD;
          9. Patient has undergone a wide excision for their primary melanoma (&gt;1 cm in dimension)&#xD;
             or complex reconstruction (rotation, free flap, or skin graft of any type).&#xD;
&#xD;
             Breast Cancer Patients&#xD;
&#xD;
         10. The patient has bilateral primary breast cancers or multiple tumors within their&#xD;
             breast.&#xD;
&#xD;
         11. Patient has had prior surgical procedures such as breast implants, reduction&#xD;
             mammoplasty, or axillary surgery.&#xD;
&#xD;
         12. Patient is scheduled for bilateral mastectomy unless for cosmetic reasons and the&#xD;
             contraindicated breast will not undergo lymph node mapping.&#xD;
&#xD;
         13. Patient has had preoperative radiation therapy to the affected breast or axilla.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon A Blackburn</last_name>
    <role>Study Director</role>
    <affiliation>Navidea Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Califonia Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Care Specialists</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, Hoh CK, Limmer KK, Krontiras H, Frazier TG, Cox C, Avisar E, Faries M, King DW, Christman L, Vera DR. Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol. 2013 Aug;20(8):2590-9. doi: 10.1245/s10434-013-2887-8. Epub 2013 Mar 17.</citation>
    <PMID>23504141</PMID>
  </results_reference>
  <results_reference>
    <citation>Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, Faries MB, Averbook BJ, Martinez SR, Puleo CA, Messina JL, Christman L, Wallace AM. Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013 Feb;20(2):680-8. doi: 10.1245/s10434-012-2612-z. Epub 2012 Oct 3.</citation>
    <PMID>23054107</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2010</study_first_posted>
  <results_first_submitted>April 13, 2013</results_first_submitted>
  <results_first_submitted_qc>April 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2013</results_first_posted>
  <disposition_first_submitted>March 28, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2012</disposition_first_posted>
  <last_update_submitted>June 6, 2013</last_update_submitted>
  <last_update_submitted_qc>June 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoseek</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Experimental</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lymphoseek, Lymphatic Mapping, Injection</title>
          <description>Melanoma and breast cancer patients to receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 163 participants who enrolled in the trial, 153 were administered the study agent, Lymphoseek, and therefore this participant number is used for the baseline analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Lymphoseek</title>
          <description>Enrolled patients who were administered any injection of Lymphoseek.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concordance of Blue Dye and Lymphoseek</title>
        <description>The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.</description>
        <time_frame>Surgery after injections of Lymphoseek and blue dye</time_frame>
        <population>All enrolled patients who were injected with both Lymphoseek and blue dye, who underwent surgery and had at least one lymph node stained intraoperatively by blue dye, and for whom the tissue type (lymphatic/non-lymphatic) and pathology status (presence/absence of tumor cells) was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.</description>
          </group>
        </group_list>
        <measure>
          <title>Concordance of Blue Dye and Lymphoseek</title>
          <description>The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.</description>
          <population>All enrolled patients who were injected with both Lymphoseek and blue dye, who underwent surgery and had at least one lymph node stained intraoperatively by blue dye, and for whom the tissue type (lymphatic/non-lymphatic) and pathology status (presence/absence of tumor cells) was confirmed.</population>
          <units>Proportion of Lymph Nodes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lymph Nodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0000" lower_limit="0.9840" upper_limit="1.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reverse Concordance of Blue Dye and Lymphoseek</title>
        <description>The proportion of lymph nodes detected intraoperatively by Lymphoseek that were also detected by blue dye.</description>
        <time_frame>Surgery after injections of Lymphoseek and blue dye</time_frame>
        <population>All enrolled patients who were injected with both Lymphoseek and blue dye, who underwent surgery and had at least one lymph node detected by Lymphoseek (at ≥ 3σ count) in vivo, and for whom the tissue type (lymphatic/non-lymphatic) and pathology status (presence/absence of tumor cells) was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Reverse Intent-To-Treat</title>
            <description>Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.</description>
          </group>
        </group_list>
        <measure>
          <title>Reverse Concordance of Blue Dye and Lymphoseek</title>
          <description>The proportion of lymph nodes detected intraoperatively by Lymphoseek that were also detected by blue dye.</description>
          <population>All enrolled patients who were injected with both Lymphoseek and blue dye, who underwent surgery and had at least one lymph node detected by Lymphoseek (at ≥ 3σ count) in vivo, and for whom the tissue type (lymphatic/non-lymphatic) and pathology status (presence/absence of tumor cells) was confirmed.</population>
          <units>Proportion of Lymph Nodes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lymph Nodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6058" lower_limit="0.5546" upper_limit="0.6554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lymphoseek</title>
          <description>Enrolled patients who were administered any injection of Lymphoseek.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Ophthalmic</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Seroma</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI shall not submit a publication to journals or professional societies without the prior written approval of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Frederick Cope</name_or_title>
      <organization>Navidea Biopharmaceuticals</organization>
      <phone>614-793-7500 ext 140</phone>
      <email>fcope@navidea.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

